Clinical Trials Logo

Fallopian Tube Cancer clinical trials

View clinical trials related to Fallopian Tube Cancer.

Filter by:

NCT ID: NCT05527184 Recruiting - Endometrial Cancer Clinical Trials

First in Human Study of IMGN151 in Recurrent Endometrial Cancer and Recurrent, High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers

Start date: January 11, 2023
Phase: Phase 1
Study type: Interventional

IMGN151-1001 is a Phase 1, first in human, open-label dose-escalation and expansion study in adult patients with recurrent endometrial cancer, recurrent, high-grade serous epithelial ovarian, primary peritoneal, or fallopian tube cancers.

NCT ID: NCT05446298 Recruiting - Ovarian Cancer Clinical Trials

ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer

PRESERVE-004
Start date: December 22, 2022
Phase: Phase 2
Study type: Interventional

This is a study to test the safety and efficacy with the combination of a next generation anti-CTLA-4 antibody, ONC-392, and anti-PD-1 antibody, pembrolizumab, in platinum resistant ovarian cancer patients.

NCT ID: NCT05445778 Recruiting - Ovarian Cancer Clinical Trials

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA)

Start date: December 27, 2022
Phase: Phase 3
Study type: Interventional

GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRĪ±) expression.

NCT ID: NCT05429970 Recruiting - Ovarian Cancer Clinical Trials

A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)

Start date: June 17, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to see if propranolol and etodolac along with mind-body resilience training/MBRT and music therapy help participants who are experiencing physiological stress before, during, and after primary debulking surgery/PDS or IDS and also if it's better than the standard-of-care approach (no intervention for reducing stress).

NCT ID: NCT05377996 Recruiting - Breast Cancer Clinical Trials

A Study of XMT-1660 in Participants With Solid Tumors

Start date: August 15, 2022
Phase: Phase 1
Study type: Interventional

A Study of XMT-1660 in Solid Tumors

NCT ID: NCT05287451 Recruiting - Ovarian Cancer Clinical Trials

Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study

Start date: May 10, 2022
Phase: N/A
Study type: Interventional

This is a prospective preference study that will evaluate non-inferiority of the innovative treatment (RRS with delayed RRO) as compared to the standard treatment (RRSO) with respect to high grade serous (ovarian) cancer incidence

NCT ID: NCT05281471 Recruiting - Clinical trials for Fallopian Tube Cancer

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Start date: August 31, 2022
Phase: Phase 3
Study type: Interventional

The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice of chemotherapy and bevacizumab in women diagnosed with platinum-resistant/refractory ovarian cancer (includes fallopian tube cancer and primary peritoneal cancer). This Phase III trial builds on the efficacy and safety data reported in the previous Phase II VIRO-15 trial with promising objective response rate and progression-free survival observed in heavily pre-treated patients with platinum-resistant/refractory ovarian cancer. The phase II results also showed that the intra-peritoneal route of delivery was efficient in generating tumor cell killing and immune activation, and led to clinical reversal of platinum-resistance or refractoriness in this difficult-to-treat patient population.

NCT ID: NCT05256576 Recruiting - Frailty Clinical Trials

KORE-Innovation: a Prospective, Multi-site Clinical Trial to Implement and Analyse the Effects of an Innovative Perioperative Care Pathway to Reduce Complications for Patients With Ovarian Cancer

KORE
Start date: July 1, 2020
Phase: N/A
Study type: Interventional

KORE-Innovation is a multi-center clinical study aiming to implement and analyze an innovative care pathway to reduce perioperative complications for patients undergoing surgical treatment for ovarian cancer. This is achieved by a structured, multidisciplinary implementation of the ERAS pathway, as well as introducing a tri-modal prehabilitation program, following a comprehensive frailty-assessment. The patient-individualized prehabilitation program consists of a structured plan to improve physical fitness, nutritional status, as well as patient empowerment. The aim of the study is to reduce perioperative morbidity and mortality, as well as improvement in quality of life.

NCT ID: NCT05220033 Recruiting - Ovarian Cancer Clinical Trials

Journey Ahead: Enhancing Coping and Communication for Women Diagnosed With Gynecological Cancer

Start date: July 14, 2020
Phase: N/A
Study type: Interventional

This study looks at how well the Journey Ahead intervention works in improving coping and communication skills in participants with gynecologic cancers.

NCT ID: NCT05198804 Recruiting - Ovarian Cancer Clinical Trials

A Study of ZN-c3 and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer

Start date: January 27, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2 study to evaluate the safety, clinical activity, pharmacokinetics (PK), and pharmacodynamics (PD) of ZN-c3 in combination with niraparib in subjects with platinum-resistant ovarian cancer.